ProCE Banner Activity

GIMEMA ALL2820: Intermediate Analysis of Phase III Trial of First-line Ponatinib + Blinatumomab in Adults With Ph+ Acute Lymphoblastic Leukemia

Conference Coverage
Slideset

Intermediate analysis of phase III GIMEMA ALL2820 trial showed that first-line treatment with ponatinib in induction and blinatumomab in consolidation was associated with approximately 95% disease-free survival and overall survival rates at 1 year in adults with Ph+ acute lymphoblastic leukemia.

Released: December 13, 2024

Expiration: December 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation